Wilson developed a novel therapeutic for Wilson Disease, a rare genetic disease characterized by excess copper storage. Alexion Pharmaceuticals acquired Wilson Therapeutics in 2018 for $855 million.

Latest news

Valneva Announces the Pricing of its Initial Public Offering on Nasdaq
May 11, 2021

Saint-Herblain (France), May 6, 2021  – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for […]

Valneva Initiates Phase 3 Clinical Trial for its Inactivated,
Adjuvanted COVID-19 Vaccine Candidate, VLA2001
April 29, 2021

Saint-Herblain (France), April 21, 2021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic […]

Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
April 6, 2021

April 6, 2021 VLA2001 was well tolerated with no safety concerns identified In the high dose group : IgG seroconversion […]

eXmoor pharma secures £12m ($17m) from healthcare investment firm MVM marking milestone towards significant expansion plans
March 16, 2021

eXmoor, the expert cell and gene therapy (CGT) services company (Bristol, England), has announced an initial investment of £12m ($17m) […]

Hologic announces acquisition of Biotheranostics
January 5, 2021

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that it has agreed to acquire Biotheranostics, Inc., […]

MVM invests in GT Medical
November 23, 2020

GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced it has […]

Valneva announces major COVID-19 vaccine partnership with UK government
September 14, 2020

– UK Government has secured supply of 60 million doses at a cost of €470 million with options over another […]

MVM invests in Paragon 28
August 15, 2020

Paragon 28, Inc., a leading orthopedic foot and ankle company, today announced the completion of a Series B financing. The […]

Valneva confirms participation in UK government COVID-19 vaccine response program
July 20, 2020

Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, today confirmed its participation in […]

MDxHealth Announces Growth Investment from MVM Partners
May 18, 2020

Press release Regulated information – Inside information IRVINE, CA, and HERSTAL, BELGIUM – 27 April 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the “Company” […]